Literature DB >> 8315576

Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease.

G E Harb1, B K Alldredge, R Coleman, M A Jacobson.   

Abstract

To evaluate the incidence, characteristics, and risk factors of adverse drug reactions (ADRs) in patients with human immunodeficiency virus (HIV) disease, we conducted was a prospective observational study of inpatients with HIV disease. The study was conducted in a public teaching hospital affiliated with the University of California, San Francisco. We reviewed daily the hospital records of all eligible inpatients throughout their hospitalization for potential ADRs. Potential ADRs were independently evaluated by two of the authors with regard to the extent of their causal association(s) with implicated drug(s) using a previously validated algorithm. Type (A, augmented; B, bizarre) and severity (mild, moderate, severe) were also evaluated. Among 495 patient admissions involving 390 eligible patients, 173 potential ADRs were identified, of which 118 (68.2%) had a probable or definite causal relationship to the implicated drugs. These probable or definite ADRs occurred among 79 (20%) eligible patients; 82 ADRs (69.5%) were classified as augmented (type A) and 36 (30.5%) were classified as bizarre (type B) reactions. Skin rash was the most frequent (17%) ADR encountered. Of the medications causing ADRs, 70% were antimicrobial drugs. Significant independent risk factors for developing ADRs included advanced stage of HIV disease, intake of a greater number of medications, and longer hospital stay. A high percentage of patients with HIV disease developed ADRs. Skin rash was the single most common kind of ADR. Advanced stage of illness and prolonged drug exposure were the only risk factors for ADRs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8315576

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  6 in total

1.  Pyrexia of undetermined origin in advanced HIV disease.

Authors:  C M Tang; C P Conlon; R F Miller
Journal:  Genitourin Med       Date:  1997-08

Review 2.  Immunosenescence and hurdles in the clinical management of older HIV-patients.

Authors:  Marco Ripa; Stefania Chiappetta; Giuseppe Tambussi
Journal:  Virulence       Date:  2017-02-21       Impact factor: 5.882

Review 3.  Human immunodeficiency virus (HIV) infection. Does it increase susceptibility to adverse drug reactions?

Authors:  G E Harb; M A Jacobson
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

4.  Frequency and cost of serious adverse drug reactions in a department of general medicine.

Authors:  N Moore; D Lecointre; C Noblet; M Mabille
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

5.  Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study.

Authors:  Ushma Mehta; David N Durrheim; Marc Blockman; Tamara Kredo; Ronald Gounden; Karen I Barnes
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

6.  ADVERSE EVENTS TO FIRST LINE ANTI-TUBERCULOSIS DRUGS IN PATIENTS CO-INFECTED WITH HIV AND TUBERCULOSIS.

Authors:  O S Michael; O M Sogaolu; F A Fehintola; O M Ige; C O Falade
Journal:  Ann Ib Postgrad Med       Date:  2016-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.